NCT03128879View on ClinicalTrials.gov

Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL

PHASE2RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

June 16, 2017

Primary Completion Date

May 31, 2027

Study Completion Date

May 31, 2027

Conditions
Chronic Lymphocytic Leukemia
Interventions
DRUG

Ibrutinib

Given PO

DRUG

Venetoclax

Given PO

DRUG

Acalabrutinib

Given BID

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT03128879 - Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL | Biotech Hunter | Biotech Hunter